Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

Pressmeddelanden   •   Mar 20, 2019 11:31 CET

Solna, Sweden & Boston, USA, March 20, 2019. Affibody AB and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases.

Affibody Announces Fully Guaranteed Rights Issue

Pressmeddelanden   •   Feb 22, 2019 09:00 CET

Solna, Sweden, February 22, 2019. Affibody Medical AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the decision to carry out a capitalization of approximately SEK 150 million through a fully guaranteed rights issue.

Year End Report 2018

Pressmeddelanden   •   Feb 21, 2019 17:12 CET

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Year End Report for 2018.

Affibody Completes Enrollment in Phase 2 Psoriasis Trial of ABY-035

Pressmeddelanden   •   Feb 20, 2019 09:00 CET

Solna, Sweden, February 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of enrollment in the Company’s Phase 2 proof-of-concept study of ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).

Affibody Announces Option Exercise by Biotest

Pressmeddelanden   •   Dec 04, 2018 07:15 CET

Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that its partner Biotest, a Germany-based biotherapeutic company, has exercised an option under the two companies’ ongoing collaboration.

Interim Report – January to September 2018

Pressmeddelanden   •   Nov 16, 2018 08:30 CET

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2018.

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Pressmeddelanden   •   Sep 24, 2018 13:00 CEST

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that a major Nordic study (“Affibody-3”) will begin using Affibody’s PET imaging agent ABY-025.

Interim Report – January to June 2018

Pressmeddelanden   •   Aug 23, 2018 08:15 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter 2018.

Affibody Presents at Anglonordic Life Science

Pressmeddelanden   •   Maj 21, 2018 09:00 CEST

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Anglonordic Life Science conference, a UK and Nordic life science conference.

Interim Report – January to March 2018

Pressmeddelanden   •   Maj 18, 2018 09:00 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter 2018.

Bilder & Videor 1 bild

Kontaktpersoner 4 kontaktpersoner

Om Affibody

Developing Next Generation Biopharmaceuticals

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing. Affibody AB is a holding of Patricia Industries. For more information on Affibody, please visit the company’s website at www.affibody.com

Adress

  • Affibody
  • Gunnar Asplunds Allé 24
  • SE-171 69 SOLNA